Copyright
©2013 Baishideng Publishing Group Co.
World J Radiol. Aug 28, 2013; 5(8): 267-274
Published online Aug 28, 2013. doi: 10.4329/wjr.v5.i8.267
Published online Aug 28, 2013. doi: 10.4329/wjr.v5.i8.267
Treatment | Complete response | Overall survival |
RT alone | 61% | 40% |
RT + carboplatin | 66% | 45% |
RT + cisplatin | 82% | 62% |
RT + cisplatin + 5-FU | 87% | 65% |
Study | No. of patients | A’ phase | CR | B’ phase 6 wk later |
RTOG 85-12[17] | 42 | TURBT, 20 × 2 Gy = 40 Gy + CDDP | 66% | 12 × 2 = 24 Gy + CDDP |
RTOG 88-02[18] | 91 | TURBT, NACT 2 × MCV, 22 × 1.8 = 39.6 Gy + CDDP | 75% | 14 × 1.8 = 25.2 Gy + CDDP |
RTOG 89-03[8] | 123 | TURBT, NACT 2 × MCV vs no NACT-22 × 1.8 = 39.6 Gy + CDDP | 61% vs 55% | 14 × 1.8 = 25.2 Gy + CDDP |
RTOG 95-06[19] | 34 | TURBT, (3 Gy × 2 per day) × 4 = 24 Gy + 5-FU/CDDP | 67% | (2.5 Gy × 2 per day) × 4 = 20 Gy + 5-FU/CDDP |
RTOG 97-06[20] | 47 | TURBT, (1.8 Gy + 1.6 Gy per day) × 12 = 40.8 Gy + CDDP | 74% | (1.5 × 2 per day) × 8 = 24 Gy + CDDP→ACT 3MCV1 |
RTOG 99-06[21] | 80 | (1.6 + 1.5 per day) × 13 d = 40.3 + CDDP/paclitaxel | 81% | (1.5 x 2 per day) × 8 = 24 Gy + CDDP/paclitaxel |
Housset et al[10] | 54 | (3 Gy × 2 per day) × 4 = 24 Gy + CDDP/5-FU | 74% | (2.5 Gy × 2 per day) × 4 = 20 Gy +CDDP/5-FU) |
Given et al[22] | 93 | NACT 2-3 × MVAC/MCV→36 × 1.8 = 64.8 Gy + CDDP | 63% | |
Fellin et al[23] | 56 | NACT 2 × MCV→20 × 2 = 40 Gy + CDDP | 50% | 12 × 2 = 24 Gy + CDDP |
Kachnic et al[24] | 106 | TURBT, NACT 2 × MCV→RCT: 25 × 1.8 = 45 Gy + CDDP | 66% | 11 × 1.8 = 19.8 Gy + CDDP) |
Arias et al[25] | 50 | TURBT, NACT 2 × MVAC→25 × 1.8 = 45 Gy + CDDP | 68% | 10 × 2 = 20 Gy |
Zapatero et al[26] | 40 | TURBT, NACT 3 × MCV→30 × 2 = 60 Gy | 70% | |
Chen et al[27] | 23 | TURBT, 30 × 2 = 60 Gy or 34 × 1.8 Gy = 61.2 Gy + CDDP/FU/leucovorin | 89% | |
Peyromaure et al[28] | 43 | TURBT, (3 Gy × 2 per day) × 4 = 24 Gy + CDDP/FU | 74% | (3 Gy × 2 per day) × 4 = 24 Gy + CDDP/FU |
Danesi et al[29] | 77 | NACT 2 × MCV→(3 × 1 Gy per day) × 23 = 69 Gy or (2 × 1.5 Gy per day) × 23 = 69 Gy | 90% | |
George et al[30] | 60 | NACT 2 × MVAC/MCV→65 Gy (median dose) + CDDP/carbo/5-FU | 75% | |
Kragelj et al[31] | 84 | 32 × 2 = 64 Gy + concurrent vinblastine | 78% | |
Cobo et al[32] | 29 | NACT 2 × MCV/GC→25 × 1.8 = 45 Gy + CDDP | 86% | 4 wk later: RT-alone 11 × 1.8 Gy = 19.8 Gy |
Perdonà et al2[33] | 43 | NACT 2 × MCV→median dose 65 Gy standard fractionation | 74.40% | |
Perdonà et al2[33] | 78 | NACT 2 × MCV→median dose 65 Gy standard fractionation + CDDP | 89.70% | |
Gamal El-Deen et al[34] | 186 | None vs NACT 2 × MCV/MVAC/GC→25 × 1.8 = 45 Gy + CDDP | 81.60% | 11 × 1.8 Gy = 19.8 Gy + the same chemo |
Sabaa et al[35] | 104 | NACT 3 × GC→20 × 2 = 40 Gy + CDDP | 78.80% | 10 × 2 = 20 Gy + CDDP |
Gogna et al[36] | 113 | 32 × 2 = 64 Gy RT + CDDP | 70% | |
Choudhury et al[37] | 50 | 20 × 2.625 = 52.5 weekly Gemcitabine | 88% | |
James et al[15] | 71 111 RT/CT arm | 20 × 2.75 Gy = 55 Gy + mitomycin C and 5-FU or 32 × 2 Gy = 64 + mitomycin C and 5-FU | 80.7%3 | |
Coppin et al[16] | 51 RT/CT-arm | 30 × 2 Gy = 60 Gy with CDDP | 47% | |
Sauer et al[11] | 95 | 50.4-59.4 Gy at 1.8 Gy plus carboplatin | 66% | |
Rödel et al[12] | ||||
Weiss et al[13] | ||||
Ott et al[14] | ||||
Sauer et al[11] | 145 | 50.4-59.4 Gy at 1.8 Gy plus cisplatin | 82% | |
Rödel et al[12] | ||||
Weiss et al[13] | ||||
Ott et al[14] | ||||
Sauer et al[11] | 49 | 50.4-59.4 Gy at 1.8 Gy plus Cisplatin/5-FU | 87% | |
Rödel et al[12] | ||||
Weiss et al[13] | ||||
Ott et al[14] |
Study | No. of patients | RT fractionation schedule | CR rate |
Gospodarowicz et al[38] | 254 | 15 × 2.33 Gy + 5 × 3 Gy | 57% |
Cowan et al[39] | 60 | 20 × 2.63 Gy = 52.5 | 75% |
Cowan et al[39] | 45 | 16 × 3.44 = 55 Gy | 71% |
Cowan et al[39] | 44 | 20 × 2.88 = 57.5 Gy | 80% |
Pos et al[40] | 50 | 20 × 2.75 Gy = 55 | 74% |
Scholten et al[41] | 123 | 6 × 6 = 36 Gy (1 fraction per week) | 44% |
Shipley et al[7] | 58 | 36 × 1.8 = 65 Gy | 56% |
De Neve et al[42] | 67 | 33 × 2 = 66 Gy | 55% |
Yavuz et al[43] | 87 | (25 × 1.8) + (15 × 1.5 as a second fraction per day the last 3 wk) = 67.5 Gy | 64% |
Borgaokar et al[44] | 163 | 20 × 2.625 = 52.5 Gy | 61% |
James et al[15] | 71 | 20 × 2.75 Gy = 55 Gy | 69.70% |
106 | 32 × 2 Gy = 64 | ||
Coppin et al[16] | 48, RT-alone arm | 30 × 2 Gy = 60 Gy | 31% |
Sauer et al[11] | 126 | 50.4-59.4 Gy at 1.8 Gy | 61% |
Rödel et al[12] | |||
Weiss et al[13] | |||
Ott et al[14] | |||
Edsmyr et al[45]12 | 85 | 32 × 2 = 64 Gy (in 8 wk) 2 wk rest after half of total dose | 36% |
83 | (3 × 1 Gy per day) × 28 = 84 Gy (in 8 wk) 3 fractions per day, 4 h apart | 59% | |
Gobolenko et al[46]12 | 43 | 30 × 2 = 60 Gy, (in 8 wk) | 16% |
2 | 26 | 2 × 1 Gy per day) × 30 = 60 Gy, (in 8 wk) | 23% |
2 | 61 | (2 × 1 Gy per day) × 35 = 70 Gy (in 9 wk) | 34% |
2 | 47 | (2 × 1.2 Gy per day) × 28 = 67.2 Gy (in 7.5 wk) | 23% |
- Citation: Plataniotis GA, Dale RG. Radio-chemotherapy for bladder cancer: Contribution of chemotherapy on local control. World J Radiol 2013; 5(8): 267-274
- URL: https://www.wjgnet.com/1949-8470/full/v5/i8/267.htm
- DOI: https://dx.doi.org/10.4329/wjr.v5.i8.267